INmune Bio Inc. Advances Revolutionary INKmune Cell Therapy in Metastatic Castration-Resistant Prostate Cancer Study
Boca Raton, Florida, April 29, 2024 - INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company dedicated to developing groundbreaking treatments that leverage the patient’s innate immune system to combat disease, is making significant strides in its Phase 1/2 trial of INKmune Natural Killer (NK) cell therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is thrilled to announce the successful completion of the first cohort in the trial, marking a major milestone in this groundbreaking research.
Following a comprehensive review conducted by the Safety Review Committee (SRC), the approval has been granted to proceed with the administration of the second dose level, referred to as cohort 2. This achievement demonstrates the remarkable safety profile and potential efficacy of INKmune therapy in treating mCRPC.
Patients enrolled in the trial will now receive the second dose of INKmune NK cell therapy, building upon the promising results observed in the first cohort. Each patient’s response to the novel treatment will be closely monitored, with the primary of assessing safety and tolerability. Additionally, the trial aims to evaluate the therapy’s potential to induce a robust and sustained immune response against metastatic castration-resistant prostate cancer.
Dr. Mitchell Steiner, CEO of INmune Bio, commented, The successful completion of our first cohort marks a significant milestone in our clinical trial evaluating INKmune therapy for mCRPC. We are excited to initiate the second cohort, as this therapy has shown great promise in potentially revolutionizing the treatment of this aggressive and devastating form of prostate cancer.
The identification of the first patient for the second cohort is a critical step forward in the trial. This patient will undergo comprehensive screening to ensure their suitability for the therapy. INmune Bio remains committed to advancing the development of INKmune cell therapy and is actively enrolling patients for this study.
INKmune NK cell therapy harnesses the natural power of the patient’s immune system to target and eliminate cancer cells. This innovative treatment holds immense potential in enhancing the body’s inherent ability to fight off cancer and potentially provide a more effective and durable treatment option for patients with mCRPC.
As the trial progresses, researchers hope to further validate the safety, efficacy, and potential clinical benefits of INKmune therapy. If successful, this cutting-edge treatment could significantly transform the landscape of metastatic castration-resistant prostate cancer treatment, offering renewed hope for patients worldwide.
Comments